REG - Oxford BioDynamics - Board Change

Oxford BiodynamicsAnnouncement

26/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260126:nRSZ2529Qa&default-theme=true

RNS Number : 2529Q  Oxford BioDynamics PLC  26 January 2026

 

 

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Board Change

Oxford, UK - 26 January 2026 - Oxford BioDynamics Plc (AIM: OBD, the
Company), a precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on its EpiSwitch® 3D
genomics platform, confirms that Stephen Diggle has stepped down as a Director
of the Company with effect from today.

As set out in the announcement of the Company's results on 16 December 2025,
after serving as Non-Executive Director for nine years, in line with good
practice Steve indicated his intention to stand down from the Board in advance
of the AGM to be held today.

Vulpes Investment Management, which is controlled by Steve, remains the
Company's largest shareholder through the Vulpes Testudo Fund and the Vulpes
Life Sciences Fund, and will nominate a new non-executive director in due
course.

Executive Chairman Iain Ross said: "Steve has served on the Board as a
Non-Executive Director since October 2016, prior to the Company's listing on
AIM later that year. On behalf of the whole Board, I would again like to thank
Steve for his support and wisdom over this long period and particularly to me
since my appointment early in 2025."

-Ends-

For further details please contact:

  Oxford BioDynamics Plc                       Tel: +44 (0)1865 518910
 Iain Ross Executive Chairman

 Paul Stockdale, CFO
 Shore Capital - Nominated Adviser and Broker  Tel: +44 (0)20 7408 4090
 Stephane Auton / Lucy Bowden
 OAK Securities - Joint Broker                 Tel: +44 (0)20 3973 3678
 Matthew Clarke / Tim Dainton / Calvin Man
 Camarco - Financial PR                        Tel: +44 (0)20 3757 4980
 Marc Cohen / Tilly Butcher / Fergus Young     OBDFinancial@camarco.co.uk

 

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://protect.checkpoint.com/v2/r02/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6NzowMDMzOmY4Y2Q3OTViOGUzNmI4OTAyZDdiNTgyYjUyMTg4NTFmNDU3Zjc2Yzg5MGY4MzMwMGIwMTkyNTJmOGIyMjIxYzM6cDpUOk4)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://protect.checkpoint.com/v2/r02/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6NzpmZWMxOjk5YTcyZWIyODkyNjI5MDY3MjhiODMwYzgwYjAzZjIzYjljNjI1ZGVlZjJmZGI3ODg1N2IzNmNhMTc3NjM5NTQ6cDpUOk4)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://protect.checkpoint.com/v2/r02/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6NzphNGVlOmZlNjM2YTAxY2E3OTIyZGJmNDZmZmZkOGUxNDc3MjVmMmE4YmVjNzFjYWE5NDg0ZWQwNGEyODAwZWEzNzJjNzM6cDpUOk4)
,  X (@OxBioDynamics) or LinkedIn
(https://protect.checkpoint.com/v2/r02/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDpjOm86Mzk1MGZhNGQ0MzJmYWY2NDg4NTZlNWZkMGM5ODEwYmM6Nzo2NmRmOjBjYzFhMTMyNDVmMDA0MjM4NmQ3YTZiN2E4NWUxODEzOWU5OWQyYzk0NDM3NjgzYTIwNjQ3NTc0NWQ4MWQyYmM6cDpUOk4)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABAMFTMTATBLF



            Copyright 2019 Regulatory News Service, all rights reserved